Acute Hepatitis E by a New Isolate Acquired in the United States

• Published in: Mayo Clinic proceedings Vol. 72; no. 12; pp. 1133 - 1136
• Main Authors: Kwo, Paul Y., Schlauder, George G., Carpenter, Herschel A., Murphy, Paul J., Rosenblatt, Jon E., Dawson, George J., Mast, Eric E., Krawczynski, Krzysztof, Balan, Vijayan
• Format: Journal Article
• Language: English
• Published: Rochester, MN Elsevier Inc 01.12.1997; Mayo Medical Ventures; Elsevier Limited
• Subjects: Acute Disease; Biological and medical sciences; Diagnosis, Differential; Hepatitis Antibodies - blood; Hepatitis E - blood; Hepatitis E - diagnosis; Hepatitis E - immunology; Hepatitis E - pathology; Hepatitis E virus - genetics; Hepatitis E virus - immunology; Human viral diseases; Humans; Immunoglobulin G - blood; Infectious diseases; Male; Medical sciences; Middle Aged; Polymerase Chain Reaction - methods; RNA, Viral - analysis; RNA-Directed DNA Polymerase; Viral diseases; Viral hepatitis; United States; North America; America; HEV; ORF; HCV; EIA; PCR; Human; Hepatic disease; Male; Serology; Infection; Case study; Polymerase chain reaction; Pathology; Viral disease; Digestive diseases; Adult; Molecular biology; Viral hepatitis E
• ISSN: 0025-6196; 1942-5546
• DOI: 10.4065/72.12.1133

To report the first case of acute hepatitis E by a novel isolate acquired in the United Statesand confirmed by nucleotide sequencing. We describe the clinical manifestations and the results of associated labora-tory studies in a man who was found to have acute hepatitis E infection. A 62-year-old man was hospitalized because of fever, abdominal pain, and jaundice. After an initial evaluation did not provide a cause, his serum was found to be positive for IgG anti-hepatitis Evirus (HEV) by three antibody assays. Serum was also positive for HEV RNA by reverse transcriptase polymerase chain reaction (PCR). Sequencing resultsfrom the PCR products demonstrated substantial differences at the nucleotide level between this strain andthe known Mexican and Burmese strains. On the basis of this initial report, HEV should be considered an etiologie agent in patients with acute non-ABC hepatitis in the United States.